Evommune shares plummeted 11.3% as its eczema drug failed to reach a major end in mid-term clinical trials.

Zhitongcaijing · 3d ago
Evommune shares plummeted 11.3% as its eczema drug failed to reach a major end in mid-term clinical trials.